Open AccessShort‐Course Paromomycin Treatment of Visceral Leishmaniasis in India: 14‐Day vs 21‐Day Treatment
Author(s) -
Shyam Sundar,
Neha Agrawal,
Rakesh Arora,
Dipti Agarwal,
Madhukar Rai,
Jaya Chakravarty
Publication year - 2009
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/605438
Subject(s) - medicine , paromomycin , regimen , group b , adverse effect , surgery , visceral leishmaniasis , group a , leishmaniasis , antibiotics , aminoglycoside , immunology , microbiology and biotechnology , biology
Treatment of visceral leishmaniasis (VL) is far from satisfactory. There is an urgent need for a therapy that is efficacious, safe, affordable, and of short duration.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom